Drugs in Dev. Endocrinology
Phase I/ Phase II
Sweden 
Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.
Product Name : Remygen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical receives Japanese patent for intralymphatic administration of diabetes vaccine Diamyd
Details : The patents protect the administration method of Diamyd® that is now being evaluated in the Phase IIb trial DIAGNODE-2, which previously showed positive results in the Phase I/II trial DIAGNODE-1.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : GAD-alum
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
